STAMFORD, Conn., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today announced it will present pre-clinical data on the Company's pan-TRK inhibitor candidate, LOXO-101, in a poster session at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Barcelona, Spain on November 18-21, 2014.

The details of the poster session are as follows:

Poster Session Title: Molecular Targeted Agents I Date: November 20, 2014 Poster Viewing Session: 18:00-19:30 (CET) Location: Exhibition Hall Poster Number: P171 Title: LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers (Abstract #391) Authors: S. Winski, B. Baer, D. Hartley, S. Rhodes, R. Wallace, S. Smith, N. Nanda, L. Kunkel, P. Lee, K. Bouhana

About Loxo Oncology Loxo Oncology develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo's development approach translates key scientific insights relating to the oncogenic drivers of cancer into drugs that are potent and highly selective for their intended targets. This approach is intended to allow for the development of drugs with a high probability of clinical success while reducing the time, costs and risks of drug development. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. For more information, visit www.loxooncology.com.  
CONTACT: Company:         Jacob S. Van Naarden         Vice President, Corporate Development and Strategy         jake@loxooncology.com                  Investors:         Peter Rahmer         The Trout Group, LLC         646-378-2973         prahmer@troutgroup.com                  Media:         Karen Sharma         MacDougall Biomedical Communications         781-235-3060         ksharma@macbiocom.com